Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.50 |
| ▸ | AKT2 | P31751 | 20/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12194050 | 0.84 | AKT1 (0.53) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16250566 | 0.84 | AKT1 (0.53) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16488547 | 0.82 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16488554 | 0.82 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL16488551 | 0.82 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3944477 | 0.81 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3131053 | 0.81 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3664890 | 0.81 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3401639 | 0.81 | AKT1 (0.52) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL3122777 | 0.80 | AKT1 (0.50) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315471-B2 | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | GENETECH, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9309204-B2 | Process for making hydroxylated cyclopentylpyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | PIK3CA, DHPS, PIK3CD | AKT1 24/4885AKT2 19/4885AKT3 30/4885 |
| US-20150099880-A1 | PROCESS OF MAKING HYDROXYLATED CYCLOPENTAPYRIMIDINE COMPOUNDS AND SALTS THEREOF | PIK3CA, PIK3CD, PIK3CG | AKT1 10/4885AKT2 6/4885AKT3 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.